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Transmission routes of Kaposi's sarcoma-associated her-
pes virus (KSHV) in the general population are poorly
understood. Sexual transmission appears to be common
in homosexual men, but heterosexual transmission has
not been clearly documented. This study aims to estimate
the prevalence of KSHV in the female general populations
of Argentina, Colombia, Costa Rica, Nigeria, Spain, Viet-
nam, Thailand and Korea to explore geographical varia-
tion and potential heterosexual transmission. Samples
and questionnaire data were available from a study organ-
ized by the International Agency for Research on Cancer
(IARC) to estimate the prevalence of distinct sexually
transmitted infections. The study includes 10,963 women
from 10 centers with questionnaire information available
on socio-demographic, reproductive and sexual lifetime
experiences, smoking habits. HPV DNA detection was pre-
viously measured. Antibodies against KSHV encoded K8.1
and orf73 were determined. Prevalence of antibodies to
any of the two antigens k8.1 or orf73 was 13.9 percent
with an important geographical variation (range = Nigeria
46%–3.8% in Spain). Antibodies increased with increas-
ing age particularly in high prevalent countries such as
Nigeria, Colombia and Costa Rica. KSHV was not related
to education, age at first sexual intercourse, number of
sexual partners, number of children, patterns of use of
oral contraceptives or presence of cervical HPV DNA. A
decreased prevalence was observed with increasing
number of cigarettes smoked per day (p = 0.000).
The study provides reliable and comparable estimates of
KSHV in diverse cultural settings across four continents
and provides a powerful indication of absence of hetero-
sexual transmission of KSHV.
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